Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - IMPEL NEUROPHARMA INC | impl-20210331.htm |
| EX-32.1 - EX-32.1 - IMPEL NEUROPHARMA INC | impl-20210331ex32_1.htm |
| EX-31.2 - EX-31.2 - IMPEL NEUROPHARMA INC | impl-20210331ex31_2.htm |
| EX-31.1 - EX-31.1 - IMPEL NEUROPHARMA INC | impl-20210331ex31_1.htm |
| EX-3.2 - EX-3.2 - IMPEL NEUROPHARMA INC | impl-20210331ex3_2.htm |
| EX-3.1 - EX-3.1 - IMPEL NEUROPHARMA INC | impl-20210331ex3_1.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, John Leaman, Chief Financial Officer of Impel NeuroPharma, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition, and results of operations of the Company.
Date: June 7, 2021
By: /s/ John Leaman___________
John Leaman
Chief Financial Officer
(Principal Financial Officer)